Not even XTL people themselves I'm afraid:) Oh and BTW the way they reported the news here on TASE was a bit sneaky in my opinion because the headline was "XTL announced today that it has completed the analysis of results from a Phase I clinical trial with XTL-2125 in patients with chronic Hepatitis".
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.